DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20150013

A novel approach in treatment of rheumatoid arthritis: Janus kinase inhibitors

Sangeeta Bhanwra, Kaza Ahluwalia

Abstract


Janus kinase (JAK) inhibitors are a new class of drugs that inhibit JAK enzymes, which are the main signal transducers for the majority of cytokines, growth factors, and interferons. These drugs work from inside the cell and are unique in a way that their action interrupts the signaling involved in the inflammation. They include drugs like ruxolitinib, tofacitinib, both of which have been US Food and Drug Administration (USFDA) approved, and many others which are currently under trials. Tofacitinib was approved by USFDA in November 2012 for oral use in patients suffering with moderate to severe rheumatoid arthritis and do not respond to methotrexate.


Keywords


Rheumatoid arthritis, Janus kinase inhibitors,Tofacitinib

Full Text:

PDF

References


Smith HS, Smith AR, Seidner P. Painful rheumatoid arthritis. Pain Physician. 2011;14(5):E427-58.

Gaffo A, Saag KG, Curtis JR. Treatment of rheumatoid arthritis. Am J Health Syst Pharm. 2006;63(24):2451-65.

Jian JJ, Wang XY, Zhang Y, Jin Y, Lin J. Advances in the inhibitors of Janus kinase. Med Chem. 2014;4(8):540-8.

U. S. Food and Drug Administration Homepage on the Internet. Washington DC: News and Events, FDA News Release, FDA Approves Xeljanz for Rheumatoid Arthritis; 2012. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm327152.htm. Updated 8 March 2015; Cited 13 November 2012.

Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest. 2008;118(11):3537-45.

O’Shea JJ, Holland SM, Staudt LM. JAKs and STATs in immunity, immunodeficiency, and cancer. N Engl J Med. 2013;368(2):161-70.

O’Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. 2013;72 Suppl 2:ii111-5.

Laurence A, Pesu M, Silvennoinen O, O’Shea J. JAK kinases in health and disease: an update. Open Rheumatol J. 2012;6:232-44.

U. S. Food and Drug Administration Homepage on the Internet. Washington DC: News Events, FDA News Release, FDA Approves First Drug to Treat a Rare Bone Marrow Disease; 2011. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm327152.htm. Updated 3 December 2014; Cited 16 November 2011.

U. S. Food and Drug Administration Homepage on the Internet. Washington DC: News & Events, FDA News Release, FDA Approves Jakafi to Treat Patients with a Chronic Type of Bone Marrow Disease; 2014. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm327152.htm. Updated 4 December 2012; Cited 4 December 2014.

Lucet IS, Fantino E, Styles M, Bamert R, Patel O, Broughton SE, et al. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood. 2006;107(1):176-83.

Bannwarth B, Kostine M, Poursac N. A pharmacokinetic and clinical assessment of tofacitinib for the treatment of rheumatoid arthritis. Expert Opin Drug Metab Toxicol. 2013;9(6):753-61.

Tanaka Y, Suzuki M, Nakamura H, Toyoizumi S, Zwillich SH, Tofacitinib study investigators. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken). 2011;63(8):1150-8.

Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367(6):495-507.

Burmester GR, Blanco R, Charles-Schoeman C, Wollenhaupt J, Zerbini C, Benda B, et al. Tofacitinib (CP 690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381(9865):451-60.

Kawalec P, Mikrut A, Wisniewska N, Pilc A. The effectiveness of tofacitinib, a novel Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol. 2013;32(10):1415-24.

Cutolo M. The kinase inhibitor tofacitinib in patients with rheumatoid arthritis: latest findings and clinical potential. Ther Adv Musculoskelet Dis. 2013;5(1):3-11.

Wollenhaupt J, Silverfield J, Lee EB, Curtis JR, Wood SP, Soma K, et al. Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies. J Rheumatol. 2014;41(5):837-52.

Vincenti F, Tedesco Silva H, Busque S, O’Connell P, Friedewald J, Cibrik D, et al. Randomized phase 2b trial of tofacitinib (CP-690,550) in de novo kidney transplant patients: efficacy, renal function and safety at 1 year. Am J Transplant. 2012;12(9):2446-56.